Janpix
Signal active
Organization
Contact Information
Overview
Janpix is discovering and developing inhibitors of Signal Transducer and Activator of Transcription (“STAT”) proteins. Most members of this family of transcription factors have been known for some time and their relevance in certain cancers, in particular for STAT3 & STAT5, validated. Inhibiting the function of STAT proteins though has been very challenging thus far and Janpix developed new chemistry to address this complex problem.
About
Industries
Biotechnology, Therapeutics, App Discovery, Oncology
Founded
2013
Employees
1-10
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Janpix headquartered in United States, North America, operates in the Biotechnology, Therapeutics, App Discovery, Oncology sector. The company focuses on Biotechnology and has secured $885.4M in funding across 32 round(s). With a team of 1-10 employees, Janpix is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Janpix, raised $17.7M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
1
Lead Investors
0
Total Funding Amount
$27.7M
Details
2
Janpix has raised a total of $27.7M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2020 | Early Stage Venture | 10.0M | ||
| 2017 | Early Stage Venture | 17.7M |
Investors
Janpix is funded by 7 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Medicxi | - | FUNDING ROUND - Medicxi | 10.0M |
| Giovanni Mariggi | - | FUNDING ROUND - Giovanni Mariggi | 17.7M |
| Janpix | - | FUNDING ROUND - Janpix | 17.7M |
| Medicxi | - | FUNDING ROUND - Medicxi | 17.7M |
Recent Activity
There is no recent news or activity for this profile.